Collaborations and Partnerships

Transfer of DNA-Damage Response Inhibitor Rights to Rakovina Therapeutics

In March 2021, Edison Oncology transferred rights to three series of novel DNA-damage response (DDR) inhibitors, including the EO2000 series of PARP inhibitors, to Rakovina Therapeutics, Inc. (TSX-V: RKV). As of December 31, 2024 Edison Oncology currently holds approximately 17% of Rakovina Therapeutics’ issued and outstanding common shares.

Rakovina Therapeutics focuses on developing innovative cancer treatments based on novel DDR technologies. The company has built a pipeline of DDR inhibitors with the goal of advancing drug candidates into human clinical trials and securing marketing approval from Health Canada, the U.S. Food and Drug Administration, and other international regulatory agencies.

For more information, please visit Rakovina Therapeutics.

Rakovina Therapeutics is headquartered in Vancouver, Canada.